Journal
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
Volume 125, Issue 3, Pages 451-458Publisher
OXFORD UNIV PRESS INC
DOI: 10.1309/15B66DQMFYYM78CJ
Keywords
ovarian carcinoma; effusions; immune response; chemokines; receptors; leukocytes; flow cytometry; survival
Categories
Ask authors/readers for more resources
We studied the clinical role of leukocyte infiltration and chemokine receptor expression in ovarian carcinoma effusions. Expression of leukocyte markers (CD3, CD4, CD8, CD4/CD8 ratio, CD16, CD19, and CD14) and chemokine receptors (CXCR1, CXCR4, CCR2, CCR5, and CCR7) was studied in 73 effusions by using flow cytometry. CXCR4, CCR5, and CCR7 were expressed abundantly on leukocytes, but all receptors were expressed rarefy on cancer cells. The presence of natural killer cells (P =. 042) and International Federation of Gynecology and Obstetrics (FIGO) stage IV disease (P =.024) predicted worse overall survival (OS). A higher percentage of CD19+ cells (P=.015) and stage IV disease (P=.008) predicted poor survival for patients with postchemotherapy fusions. Only FIGO stage retained significance as a predictor of OS (P=.035) in multivariate analysis. Chemokine receptors are expressed widely on leukocytes but rarely on carcinoma cells in ovarian carcinoma effusions, arguing against an autocrine chemokine pathway in this malignancy. Immune response parameters in ovarian cancer effusions are weak predictors of outcome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available